| Date Filed | Type | Description |
| 04/22/2021 |
GN
| Assertio Holdings, Inc. to Report First Quarter 2021 Financial Results After the Close of Markets on Thursday, May 6, 2021 |
| 02/12/2021 |
GN
| Assertio Holdings, Inc. Announces Closing of Registered Direct Offering of $34.3 Million |
| 02/12/2021 |
SC 13G/A
| Allianz Global Investors U.S. Holdings LLC reports a 0% stake in Assertio Therapeutics, Inc. |
| 02/10/2021 |
GN
| Assertio Holdings, Inc. Announces Pricing of $34.3 Million Registered Direct Offering |
| 02/05/2021 |
GN
| Assertio Holdings, Inc. Announces Pricing of $14 Million Registered Direct Offering |
| 02/03/2021 |
GN
| Assertio Announces $5.0 Million Insurance Settlement and General Corporate Updates |
| 12/29/2020 |
GN
| Assertio Announces Transfer of Listing from Nasdaq Global Select Market to Nasdaq Capital Market |
| 12/15/2020 |
GN
| Assertio Announces Restructuring Plan and Leadership Changes |
| 11/06/2020 |
GN
| Assertio Reports Third Quarter 2020 Financial Results |
| 08/07/2020 |
GN
| Assertio Reports Second Quarter 2020 Financial Results |
| 07/20/2020 |
GN
| Assertio to Release Second Quarter 2020 Financial Results and Host Webcast on August 7, 2020 |
| 06/18/2020 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)]: |
| 05/22/2020 |
8-K
| Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; T... |
| 05/19/2020 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 05/18/2020 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/11/2020 |
4
| DAWES KAREN A (Director) has filed a Form 4 on Assertio Therapeutics, Inc|
Txns:
| Sold 15,834 shares
@ $0.7914, valued at
$12.5k
|
|
| 05/11/2020 |
10-Q
| Quarterly Report for the period ended March 31, 2020 |
| 05/11/2020 |
8-K
| Quarterly results |
| 05/11/2020 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 04/24/2020 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing |
| 04/20/2020 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/20/2020 |
GN
| Assertio Therapeutics Announces its Virtual 2020 Annual Meeting on May 19, 2020, and Mailing of its Joint Proxy Statement/Prospectus |
| 04/08/2020 |
SC TO-I/A
| Form SC TO-I/A - Tender offer statement by Issuer: [Amend] |
| 04/08/2020 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 04/03/2020 |
4/A
| Bukofzer Stan (SVP, Chf Scitfc & Tech Officer) has filed a Form 4 on Assertio Therapeutics, Inc|
Txns:
| Paid exercise price by delivering 7,433 shares
@ $0.6467, valued at
$4.8k
Exercised 25,370 restricted stock units
@ $0 |
|
| 04/03/2020 |
4
| Bukofzer Stan (SVP, Chf Scitfc & Tech Officer) has filed a Form 4 on Assertio Therapeutics, Inc|
Txns:
| Paid exercise price by delivering 7,433 shares
@ $0
Exercised 25,370 restricted stock units
@ $0 |
|
| 03/31/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/26/2020 |
SC 13D
| DEPOMED INC reports a 51% stake in Zyla Life Sciences |
| 03/25/2020 |
SC TO-I/A
| Form SC TO-I/A - Tender offer statement by Issuer: [Amend] |
| 03/17/2020 |
GN
| Are Shareholders Getting a Fair Deal? Halper Sadeh LLP Investigates the Sale of These Companies – WLTW, TTPH, ASRT, MEET |
| 03/17/2020 |
8-K
| Asset disposition|
Docs:
|
"Agreement and Plan of Merger by and among Assertio Therapeutics, Inc., Alligator Zebra Holdings, Inc., Alligator Merger Sub, Inc., Zebra Merger Sub, Inc. and Zyla Life Sciences",
"Form of Voting and Support Agreement by and among Alligator Zebra Holdings, Inc. and certain Zyla stockholders",
"Form of Voting and Support Agreement by and among Alligator Zebra Holdings, Inc. and certain Zyla stockholders",
"Transition Agreement by and among Assertio Therapeutics, Inc. and Arthur Higgins",
"Assertio Therapeutics Agrees to Merge with Zyla Life Sciences to Create Synergistic Portfolio of Neurology and Non-Opioid Pain Products Combined Company Pro Forma 2019 Net Product Sales of Approximately $128 Million 1 Expects to Capture Significant Operating and Product Portfolio Synergies Upwards of $40 Million, Accelerating Revenue Growth and Creating Shareholder Value Arthur Higgins to Become the Non-Executive Chairman and Todd Smith to be Named President and CEO of Combined Company",
"Employee FAQs",
"Investor Presentation" |
|
| 03/17/2020 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 03/16/2020 |
GN
| Assertio Therapeutics Agrees to Merge with Zyla Life Sciences to Create Synergistic Portfolio of Neurology and Non-Opioid Pain Products |
| 03/11/2020 |
SC TO-I
| Form SC TO-I - Tender offer statement by Issuer: |
|